Corealis CDMO signs an agreement with ArchiMed

ArchiMed, a private equity specialist in the healthcare sector, is the lead investor in an alliance recapitalizing Corealis Pharma. ArchiMed and another investor, Caisse de depot et placement de Quebec, a pension fund in Canada, are joining the founders and management in this recapitalization. The partnership will further expand the drug development services that Corealis offers as a contract development and manufacturing organization to small and mid-sized biotech and pharmaceutical companies.

Based in Laval, Quebec, Corealis is a CDMO in the Americas for the formulation and manufacturing of solid dosage oral pharmaceutical products – tablets, capsules and granules – in pre-clinical and pre-marketing clinical trials.

“ArchiMed understood our strategy and came up with an interesting investment thesis,” said Yves Roy, President of Corealis. “We have turned down several higher offers from potential suitors – commercial and financial. Like us, ArchiMed understands the significant potential of this industry and what it takes to take it to the next level. As partners, we will be able to capitalize on market leadership, by aggressively developing our scientific strengths in R&D and our best regulatory compliant manufacturing processes. [such regulatory compliant processes are known as Good Manufacturing Practices or GMP].” Roy and fellow founders Patrick Gosselin and Yves Mouget retain a significant stake in Corealis.

“With the expertise of Corealis, the influence of CDPQ and our knowledge of the international healthcare landscape, we have the perfect combination to scale rapidly in a growing industry,” says Robin Filmer-Wilson, ArchiMed Partner . Since 2019, Corealis sales have recorded an average annual growth of more than 15%, a pace that is expected to accelerate as the outsourcing of drug formulation increases in response to inflation and more demanding regulations. . The deal was closed by ArchiMed’s Pharmaceutical Services team, aided by ArchiMed’s MedTalents®, a global network of senior healthcare executives associated with ArchiMed who identify, facilitate and advise deals and advise companies in the wallet.

MED III invests in the small cap healthcare sectors in Europe and the Americas, in partnership with owners and managers.

Fairmount Partners, a leading investment bank in the pharmaceutical services industry, served as exclusive financial advisor to Corealis.

Previous Irdai orders insurers to stop displaying ads for assistance services unrelated to insurance claims
Next Eni, CNH Industrial and Iveco Group signed a memorandum of